Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment Resistant Clear all
Completed Phase 1 Interventional

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT03552471
View directory record Official record
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Serous Carcinoma, Recurrent Uterine Carcinosarcoma, Platinum Resistant Ovarian Cancer
Interventions
Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study, Rucaparib Camsylate
Other · Biological · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Jun 27, 2026, 6:50 AM EDT
Terminated Not applicable Interventional Results available

Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)

NCT01426516
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Genecept Assay
Device
Lead sponsor
Genomind, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Jun 27, 2026, 6:50 AM EDT
Terminated Phase 3 Interventional Results available

Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone

NCT00376259
View directory record Official record
Conditions
Hepatitis B
Interventions
telbivudine, adefovir dipivoxil
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
San Diego, California • San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Jun 27, 2026, 6:50 AM EDT
Completed Not applicable Interventional

Establishing Clinical Utility Evidence for Chronic Disease Management Testing Patient Study

NCT05910684
View directory record Official record
Conditions
Cardiometabolic Syndrome
Interventions
Aegis CDM Test and Educational Materials
Diagnostic Test
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Jun 27, 2026, 6:50 AM EDT
Terminated Phase 2 Interventional

Concentrated Saline Infusions and Increased Dietary Sodium With Diuretics for Heart Failure With Kidney Dysfunction

NCT00575484
View directory record Official record
Conditions
Congestive Heart Failure, Renal Insufficiency
Interventions
Hypertonic saline, then oral sodium chloride, Normal saline, then oral placebo capsule
Drug
Lead sponsor
Barnes-Jewish Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Jun 27, 2026, 6:50 AM EDT
Withdrawn Not applicable Interventional

Treatment Resistant Epilepsy and N-Acetyl Cysteine

NCT02054949
View directory record Official record
Conditions
Autistic Disorder, Seizures, Irritability
Interventions
N-Acetyl Cysteine (NAC)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
6 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Jun 27, 2026, 6:50 AM EDT
Completed Not applicable Interventional Results available

Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder

NCT00617396
View directory record Official record
Conditions
Functional Bowel Disorders
Interventions
Quetiapine (50 mg/day-100mg/day)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jun 27, 2026, 6:50 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

NCT00002213
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir, Efavirenz
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Berkeley, California • Los Angeles, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 27, 2026, 6:50 AM EDT
Recruiting Phase 1 Interventional

GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy

NCT06636123
View directory record Official record
Conditions
Castration-resistant Prostate Cancer
Interventions
Investigational Agent Administration
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jun 27, 2026, 6:50 AM EDT
Recruiting Phase 2 Interventional

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

NCT06616597
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma), Metastatic Prostate Cancer
Interventions
Abiraterone acetate, Dexamethasone, Metronidazole
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jun 27, 2026, 6:50 AM EDT
Not listed Phase 1 Interventional

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

NCT04519476
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
Selinexor, Lenalidomide, Methylprednisolone
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Jun 27, 2026, 6:50 AM EDT
Terminated Phase 2 Interventional

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

NCT04754425
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Erdafitinib
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 27, 2026, 6:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

NCT01505868
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Small Cell Carcinoma
Interventions
Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jun 27, 2026, 6:50 AM EDT
Terminated Phase 1 Interventional

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

NCT03608618
View directory record Official record
Conditions
Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma, Adenocarcinoma of the Ovary, Primary Peritoneal Carcinoma
Interventions
MCY-M11, Cyclophosphamide
Biological · Drug
Lead sponsor
MaxCyte, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Rockville, Maryland • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jun 27, 2026, 6:50 AM EDT
Completed Not applicable Interventional

Effectiveness of Acupuncture for Depressed Patients Taking Antidepressant Medications

NCT01633996
View directory record Official record
Conditions
Depression
Interventions
Acupuncture
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2012 · Synced Jun 27, 2026, 6:50 AM EDT
Terminated Phase 4 Interventional Results available

BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia

NCT05102162
View directory record Official record
Conditions
Pneumonia
Interventions
Cefepime, Meropenem, or Piperacillin/Tazobactam
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Jun 27, 2026, 6:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

DIETFITS Study (Diet Intervention Examining the Factors Interacting With Treatment Success

NCT01826591
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Low-Carbohydrate Diet, Low-Fat Diet, Mobile App
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 50 Years
Enrollment
609 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jun 27, 2026, 6:50 AM EDT
Completed Phase 4 Interventional

Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

NCT00287820
View directory record Official record
Conditions
Schizophrenia, Diabetes, Metabolic Syndrome, Hyperglycemia
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2011 · Synced Jun 27, 2026, 6:50 AM EDT
Terminated Phase 1 Interventional

Adaptive tDCS for Treatment-Resistant MDD

NCT02942368
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
tDCS
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jun 27, 2026, 6:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

NCT05261490
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Interventions
maplirpacept (PF-07901801), Pegylated Liposomal Doxorubicin (PLD)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Santa Monica, California • Miami, Florida • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Jun 27, 2026, 6:50 AM EDT
Active, not recruiting Phase 1 Interventional

Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)

NCT00368082
View directory record Official record
Conditions
Lymphoma, Hodgkin's Disease, Relapse, Lymphoma, Non-Hodgkin
Interventions
TGFbeta resistant LMP-specific CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2031
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jun 27, 2026, 6:50 AM EDT
Active, not recruiting Phase 1 Interventional

TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC

NCT02065362
View directory record Official record
Conditions
EBV-positive Nasopharyngeal Carcinoma
Interventions
DNR.NPC-specific T cells, DNR.NPC-specific T cells + cyclophosphamide + fludarabine
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jun 27, 2026, 6:50 AM EDT
Recruiting Phase 2 Interventional

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07287150
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
Inavolisib, Enzalutamide, Abiraterone, Docetaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
San Francisco, California • Iowa City, Iowa • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 27, 2026, 6:50 AM EDT
Terminated Phase 3 Interventional

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

NCT00123890
View directory record Official record
Conditions
HIV Infection
Interventions
GW873140
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
34
States / cities
Tucson, Arizona • Laguna Beach, California • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Jun 27, 2026, 6:50 AM EDT